Yin C, Ackermann S, Ma Z, Mohanta SK, Li Y, Nietzsche S, Westermann M,
Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S,
Markus Hildner M, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger
T, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR.
ApoE attenuates unresolvable inflammation by complex formation with
activated C1q.
It is entitled “Complement component C5 iRNA compositions and methods of use” and it relates to iRNA （should be siRNA）compositions targeting the complement component C5 gene, and methods of using to treat a complement component C5-associated disease, e.g., Alzheimer’s disease, atherosclerosis, or inflammation of the choroid plexus (ChP).
This is a joint patent with Alnylam Pharmaceuticals, Inc.
This is a joint patent with Alnylam Pharmaceuticals, Inc.
